This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Whilst the British considered this consistent with the Balfour Declaration's commitment to protect the rights of non-Jews, many Zionists saw it as a repudiation of the declaration. Although this policy lasted until the British surrendered the Mandate in 1948, it served only to highlight the fundamental difficulty for Britain in carrying out the Mandate obligations. Britain's involvement in this became one of the most controversial parts of its Empire's history and damaged its reputation in the Middle East for generations. According to historian Elizabeth Monroe: "measured by British interests alone, [the declaration was] one of the greatest mistakes in [its] imperial history" which greatly damaged Britain. However, others argue that this approach ignores the emergence of nationalism and the dismantling of major empires throughout the world, and the Britain would likely not have been able to maintain its presence in the Middle East in any case. The 2010 study by Jonathan Schneer, specialist in modern British history at Georgia Tech, concluded that because the build-up to the declaration was characterized by "contradictions, deceptions, misinterpretations, and wishful thinking", the declaration sowed dragon's teeth and "produced a murderous harvest, and we go on harvesting even today". The foundational stone for modern Israel had been laid, but the prediction that this would lay the groundwork for harmonious Arab-Jewish cooperation proved to be wishful thinking.
In Finland, commonly eaten species include (but are not limited to) Russula vinosa, Russula vesca, Russula paludosa, Russula decolorans, Russula xerampelina and Russula claroflava. In Thailand, russulas collected by locals and sold in roadsides and local markets include Russula alboareolata, Russula lepida, Russula nigricans, Russula virescens, and Russula xerampelina. Edible russulas in Nepal include Russula flavida and Russula chlorides. The tropical Chinese species Russula griseocarnosa, misidentified as the European R. vinosa until 2009, is commercially collected as food and medicine.
=== Research conducted === In 1963, Nikolai Kardashev and Gennady Borissovich Sholomitskii studied the CTA 102 radio source on the 920 MHz band from the Crimea Deep Space Station, looking for signs of a Type III civilization. CTA 102 had been discovered by Sholomitskii a year earlier, and Kardashev quickly saw it as a possible artificial source to study in order to validate his classification. The observation lasted until February 1965, and on April 12, Sholomitskii announced to the press (via the Russian ITAR-TASS) that Soviet astronomers had discovered a signal that could be of extraterrestrial origin. On April 14, he gave a conference in Moscow where he repeated his announcement; but by November 1964, two American astronomers had identified CTA 102 as a quasar, and their publication definitively closed the "CTA 102 case". It was the study of this source that had led to the Byurakan conference in 1964. In 1975 and 1976, the American astronomers Frank Drake and Carl Sagan searched at Arecibo for signs of Type II civilizations in four galaxies of the Local Group: M33, M49, Leo I and Leo II. The year before, the two men had sent mankind's first message to M13. The results were published as "The Search for Extraterrestrial Intelligence" in Scientific American in May 1975. In 1976, Kardashev, Troitskii, and Gindilis used the RATAN-600 radio telescope in the North Caucasus to search for signals from Type II or III civilizations in the Milky Way and other nearby galaxies.
== Types == Many rheumatic disorders of chronic, intermittent pain (including joint pain, neck pain or back pain) have historically been caused by infectious diseases. Their etiology was unknown until the 20th century and not treatable. Postinfectious arthritis, also known as reactive arthritis, and rheumatic fever are other examples. In the United States, major rheumatic disorders are divided into 10 major categories based on the nomenclature and classification proposed by the American College of Rheumatology (ACR) in 1983.
Sources: en.wikipedia.org
Many of his reports, which he wrote primarily for the newspaper Frankfurter Allgemeine Zeitung, the news magazine Der Spiegel and the weekly newspaper Die Zeit, were also published in expanded versions as books, becoming bestsellers. In cooperation with the Avicenna relief organization founded by his father Djavad Kermani, Kermani initiated fundraising campaigns for aid projects in Aceh (Indonesia), Lesbos, Madagascar and Tigray after returning from his reporting trips. Kermani's books have been translated into numerous languages. In his public statements and speeches, Kermani regularly comments on issues of society, politics and religion. Jan-Werner Müller described him in the New York Review of Books as one of Germany's most thought-provoking intellectual voices. From 2009 to 2012, Kermani was a senior fellow at the Kulturwissenschaftliches Institut (KWI) Institute for Advanced Humanities Study in Essen. In 2009, he was appointed a corresponding member of the Akademie der Wissenschaften [Academy of Sciences] in Hamburg. In the summer semester of 2010, Kermani served as guest lecturer in poetics at the Goethe University Frankfurt, where he gave the Frankfurter Poetikvorlesungen [Frankfurt Poetics Lectures], which were later published as a book entitled Über den Zufall. Jean Paul, Hölderlin und der Roman, den ich schreibe [On Contingency: Jean Paul, Hölderlin, and the Novel I Am Writing]. In the winter semester of 2011/12, Kermani delivered the Göttingen Poetics Lecture series, and in 2014, the Mainz Poetics Lecture series.
By enabling three-dimensional movement within DMF, the technology can be used even more extensively in biological applications, as it could more accurately mimic 3-D microenvironments. A large benefit of employing this type of method is that it allows for two different environments to be accessible by the droplet, which can be taken advantage of by splitting the microfluidic tasks among the two surfaces. For example, while the lower plane can be used to move droplets, the upper plate can carry out the necessary chemical and/or biological processes. This advantage can be translated into practical experiment protocols in the biological community, such as coupling with DNA amplification. This also allows for the chip to be smaller, and to give researchers more freedom in designing platforms for microdroplet analysis.
== History == BRD-6929 was first described in the scientific literature in 2005. Subsequently, it was described in greater detail in 2013 and thereafter. The drug's apparent lack of selectivity for HDAC1 and HDAC2 over HDAC3 was first described in 2022.
20 February Reg Douglas, Olympic rower (1956), British Empire and Commonwealth Games gold (1954, 1958) and silver medallist (1954) (born 1930). Sir Peter Trapski, lawyer and judge, chief District Court judge (1985–1989) (born 1935). Maata Wharehoka, weaver, Māori arts advocate, community leader (Parihaka), Ngā Tohu ā Tā Kīngi Īhaka (2015) (born 1950). 21 February – John Anderson, businessman, founder of Contiki Tours (1962) (born 1938). 24 February – Khalid Sandhu, Muslim community leader and physician, president of the Federation of Islamic Associations of New Zealand (1986–1988, 1989–1990) (born 1942). 27 February Dave Gillespie, rugby union player (Otago, Wellington, national team) (born 1934). Michael Moroney, Hall of Fame Thoroughbred racehorse trainer (Brew, Tofane, Xcellent) (born 1958).
Fully aware that it was "an extraordinarily effective but dangerous drug", and "despite [the] prevailing hostility in the medical profession as regards drug patents", Banting, Best, and Collip patented their extract in 1923, in order to have some control over its purity, quality, potency, manufacture, and sale. Although the Toronto team's initial (1922) announcements (FB.1; FB.2) and later (1923) patent application (FB.5) only spoke of "pancreatic extracts", by May 1922, they were using the name "insulin" — derived from the term "insuline" independently coined by Jean de Meyer in 1909 (JD.1, p.96) and Edward Schäfer in 1913 (ES.1, p.84) — as a generic umbrella term to label their extraction product.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。